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2Abstract
The aim of this work was to analyse the hypotensive effect of amaranth 
protein/peptides on spontaneously hypertensive rats (SHR). The mechanism of action 
of these peptides was studied in vivo and ex vivo. We also tested the effect of 
protection against gastrointestinal digestion (GID) exerted by an O:W emulsion on the 
integrity of the antihypertensive peptides. All samples tested produced a decrease in 
blood pressure (SBP). The animals treated with emulsion (GE) and emulsion+peptide 
(GE+VIKP) showed the most significant reduction in the SBP (42±2 mmHg and 35±2 
mmHg, respectively). The results presented suggest that after GID, a variety of 
peptides with biological activities were released or were resistant to this process. 
These peptides play a role in the regulation of the SBP by acting on plasma ACE, 
plasma renin and the vascular system. These results support the use of amaranth 
protein/peptides in the elaboration of functional foods for hypertensive individuals.
Key words: amaranth proteins, antihypertensive activity, protein hydrolysate, 
spontaneously hypertensive rats, renin-angiotensin system. 
31 Introduction
Hypertension is one of the risk factors associated with cardiovascular disease. 
This conditioncan be managed through regular physical activity, a healthy diet, a 
reduced sodium intake, and avoiding smoking, among others (Norris & FitzGerald, 
2013; WHO, 2013). Blood pressure is known to be regulated through a complex 
mechanism involving several interconnected metabolic pathways. Hypertension is 
characterised by an increased activity of the enzymes (mainly renin and angiotensin 
converting enzyme, ACE) belonging to the renin-angiotensin system (RAS). The 
activation of this system leads to high levels of angiotensin II, which causes blood 
vessels to contract, together with a reduction in vasorelaxation and an increase in 
theproduction of superoxide anion. Together, these phenomena lead to an increased 
NO degradation rate with the consequent decrease in its vasorelaxant effect (Aluko, 
2015a; Norris & FitzGerald, 2013). The RAS also comprises ACE2 and the peptides 
angiotensin (1-7) and angiotensin (1-9), which have opposite effects to 
angiotensinogen II (Nguyen Dinh Cat & Touyz, 2011).
The European guidelines for the management of hypertension indicate that 
functional foods might be a good alternative for patients with mild hypertension or act 
as a co-adjuvant of anti-hypertensive drugs in the treatment of moderate hypertension 
(Borghi, Urso, & Cicero, 2017). Functional foods, which can be used for either the 
treatment or the prevention of hypertension, do not cause the adverse effects of 
conventional drugs. The employment of these foods may contribute to the reduction of 
the public health expenditure destined to the cure of cardiovascular diseases (Houston, 
2019a, 2019b)
Bioactive peptides of animal and vegetal origin, as well as some components of 
functional foods, exert anti-hypertensive effects mainly through the inhibition of RAS 
enzymes and the increase of NO levels (Aluko, 2015a, 2015b, 2019; Fritz, Vecchi, 
Rinaldi, & Añón, 2011; He, Aluko, & Ju, 2014; Hernández-Ledesma, Del Mar 
4Contreras, & Recio, 2011; Martínez-Maqueda, Miralles, Recio, & Hernández-Ledesma, 
2012; Quiroga, Aphalo, Nardo, & Añón, 2017; Saleh, Zhang, & Shen, 2014; Wu, Liao, 
& Udenigwe, 2017).
Amaranth proteins are a source of bioactive peptides. Over the last years, these 
proteins have gained an interest that goes beyond their nutritional properties. In fact, 
many compounds with beneficial effects on health have been characterised, 
particularly, the biologically active peptides obtained through enzymatic hydrolysis of 
proteins from this pseudocereal (Tovar-Pérez, Lugo-Radillo, & Aguilera-Aguirre, 2018). 
Studies carried out in our laboratory have demonstrated the existence of cryptic 
peptides in reservoir proteins of amaranth grains. These peptides have proved to inhibit 
ACE and renin (Quiroga et al., 2017; Quiroga, Aphalo, Ventureira, Martínez, & Añón, 
2012; Tiengo, Faria, & Netto, 2009; E. G. Tovar-Pérez, Guerrero-Legarreta, Farrés-
González, & Soriano-Santos, 2009; Vecchi & Añón, 2009; Vilcacundo, Martínez-
Villaluenga, Miralles, & Hernández-Ledesma, 2018). Furthermore, our research group 
is the first one to have performed in vivo experiments using an amaranth hydrolysate. 
This preparation was found to reduce the blood pressure values (Fritz et al., 2011).
Thus, amaranth proteins have cryptic peptides with anti-hypertensive properties 
demonstrated both in vivo and in vitro. Based on the results reported so far, we 
consider that amaranth peptides act as hypotensive bioactive peptides through 
different mechanisms. However, the mechanism governing their anti-hypertensive 
effect has not been elucidated. The aim of this work was, therefore, to perform further 
research on the biological effect of amaranth peptides. To that end, the hypotensive 
effect of samples containing amaranth protein/peptides wastested on spontaneously 
hypertensive rats (SHR). The mechanism of action of these peptides was studied both 
in vivo and ex vivo by evaluating the quantity and the biological activity of the main 
RAS enzymes (ACE and renin). Amaranth samples were also tested on vascular 
endothelium. We also tested the effect of protection against gastrointestinal digestion 
5exerted by an O:W emulsion on the integrity of the antihypertensive peptides present in 
an amaranth hydrolyzate.
The results presented in this work will allow the development of strategies for the 
incorporation of these anti-hypertensive peptides into functional foods.
2 Materials and Methods
2.1 Chemicals
The Ratrenin ELISA kit MBS041519 and the Rat angiotensin converting 
enzyme ELISA kits MBS703086 (MyBioSource, San Diego, CA, USA) were employed 
to assess the activity of renin and ACE. All other reagents were purchased from Sigma 
(St. Louis, Missouri, USA). 
2.2 Samples
The following samples were used for in vivo assays: 
-Amaranth protein isolate (API) and hydrolysate (AH) prepared from Amaranthus 
hypochondriacus as described elsewhere (Suárez & Añón, 2019).The protein content 
was 87 ± 1 and 57 ± 2 % w/w w.b for API and AH respectively.
- VIKP peptide, which is a synthetic peptide from the 11S amaranth protein. This 
peptide has inhibitory activity on ACE (Vecchi & Añón, 2009).
-O/W 20:80 emulsions prepared with sunflower oil and 1:1 protein mixtures of API and 
AH at pH 2 and with a total protein concentration of 2% with or without the VIKP 
peptide [(API50+AH50)-2%+VIKP and (API50+AH50)-2%, respectively]. Emulsions 
were prepared according to Suárez & Añón, 2019. Emulsions were frozen at -80ºC, 
lyophilised and resuspended as required. Before administration, the resuspended 
emulsions were homogeneised with a magnetic stirring bar. 
- Commercial ACE and renin inhibitors (captopril and aliskiren, respectively) were 
employed as positive controls.
2.3 In vivo assays
2.3.1 Animals
6In vivo and ex vivo experiments were carried out at the Cardiovascular 
Laboratory of the Chair “A” of Histology, Embryology and Cytology, School of Medical 
Sciences, National University of La Plata (UNLP). The protocol for animal handling was 
approved by the Institutional Committee for the Care and Use of Laboratory Animals 
(CICUAL), protocol number P02-05-2017,School of Medical Sciences-UNLP. Sixty 
male SHR rats were acquired at the Experimentation Animals Laboratory (LAE) of the 
School of Veterinary Sciences, UNLP. The animals weighed between 210-290 g and 
had approximately 10 weeks of age at the beginning of the study.
Rats were housed in stainless steel cages, 4 animals per cage, with sterilised 
bedding (white pine wood shavings), which was changed every day. The facility had air 
conditioningand a 12 h light -12 h dark cycle. The environmental humidity was kept at 
optimum levels for the experiment and animal well-being. Food and water was provided 
ad libitum. Tap water was provided in sterilised bottles with stainless steel 
nipples.Animalswere fed with extruded balanced feed (rat-mouse, Ganave, Grupo Pilar 
S.A (Buenos Aires, Argentina).
2.3.2 Oral administration of samples
Samples indicated in 2.2 were administered to different groups of SHR rats as 
follows: 
1. Negative control group (water, GW): animals which did not receive amaranth protein. 
2. Captopril group (GC): animals treated with captopril, an ACE inhibitor. 
3. Aliskiren group (GA): animals treated with aliskiren, a renin inhibitor.
4. API group (GAPI): animals treated with API. 
5. AH group (GAH): animals treated with AH. 
6. VIKP group (GVIKP): animals treated with the synthetic in vitro anti-hypertensive 
peptide.
7. Emulsion group (GE): animals treated with API50+AH50 2% pH 2. 
8. Emulsion + VIKP group (GE+VIKP):animals treated with (API50+AH50)-2%+VIKP.  
7Samples were administered by the orogastric route with 2 ml of each sample 
dispersed in distilled water. The Gw group received 2 ml of distilled water, groups GC 
and GA received 10 mg captopril/kg and 2.5 mg aliskiren/kg, whereas groups GAPI, GAH  
and GE received 1.9 g protein/kg, group GVIKP, 50 mg peptide/kg, and group GE+VIKP, 1.9 
g protein + 50 mg peptide. Animals were divided into 8 groups of 7-8 animals each, 
except captopril and aliskirene groups in which 4 animals were used. The average 
starting SBP corresponding to 58 animals was 191± 22 mmHg. 
Indirect measurement of blood pressure
Rats were placed in a chamber at 37°C for 10 min, and then transferred to a 
standard setup (Fritz & Rinaldi, 2007) with heating pad and an acrylic restrainer, a tail 
cuff and a pulse sensor (NarcoBiosystems, Houston, TX). The systolic blood pressure 
was measured according to Fritz et al., (2011). 
In order to determine baseline values, blood pressure values were recorded at 
least three times in different days for each rat.
After recording the last baseline blood pressure value, an aqueous suspension 
of each sample was administered to each animal. Three hours after the administration, 
blood pressure values were recorded.
2.3.3 Surgical procedure
Animals were anesthetized with an intra-peritoneal injection (23 gauge needles) 
of sodium pentobarbital (25 mg/ml, 0.15 ml/100 g) and diazepam (0.25 mg/ml, 0.1 
ml/100 g). The rat’s abdominal aorta was then cannulated to collect a blood sample 
(roughly 6 ml) in heparin-coated tubes. Samples were immediately centrifuged at 4ºC 
for 15 min and 1000 xg. The plasma was separated, aliquoted and kept at -80ºC until 
used. 
2.3.4 Determination of plasma ACE and renin concentrations 
A commercial ELISA kit (Ratangiotensin converting enzyme MBS703086, 
MyBioSource, CA, USA) was employed to determine the concentration of ACE 
according to the manufacturer’s directions. This immunoassay is based on a 
8competitive inhibition. Briefly, microtitre plates are coated with ACE. Samples and 
standards are incubated together with an anti-ACE HRP-labeled conjugate to generate 
the competition.
The plasma renin concentration was determined with a commercial ELISA kit 
(Rat renin ELISA kit MBS041519 My BioSource) following the manufacturer´s 
directions. This immunoassay is a direct ELISA, which has an analytical measurement 
range of 6.25 pg/ml - 200 pg/ml. The final colour reaction was read in a microtitre plate 
reader (Biotek Synergy HT, Winooski, VT, USA) at 450 nm. 
2.3.5 Determination of plasma ACE activities 
ACE-inhibitory activity was assayed according to Suárez & Añón, (2019). 
Briefly, to determine the enzymatic activity, 50 µl of buffer [0.2 M sodium borate pH 8.3; 
2 M NaCl), 25 µl of mili Q water, 25 µl of the commercial enzyme (maximum activity 
control)], or plasma samples were incubated with 100 µl of synthetic substrate (HHL) at 
37ºC for 30 min. The reaction was stopped by heating the mixture over a water bath at 
90ºC for 15 min. After cooling, 600 µl of 0.2 M potasium pH 8.2 and 515 µl of colour 
reagent, which reacts with the hippuric acid generated during the enzymatic reaction, 
were added and stirred vigorously with a vortex and then centrifuged for 10 min at 20ºC 
and 3000 xg. The absorbance was measured at 382 nm in a spectrophotemeter 
(Beckman DU 650). 
The reaction blank was obtained by incubating the synthetic substrate with 
neither the plasma samples nor the enzyme, completing the reaction volume with mili 
Q water. 
Reaction blanks without the substrate (the HHL was replaced with 100 µl of 
borate buffer) and containing plasma samples were also included. Controls containing 
plasma samples and captopril were also assayed. 
2.4 Ex vivoexperiments
During the surgical procedure employed to obtain blood samples, the thoracic 
aorta was resected and placed in saline bubbled with 5% CO2 and 95% O2. The 
9adjacent connective tissue was carefully removed avoiding distention of the vessel and 
damage to the endothelium. The aorta was then cut into two mm long rings. The assay 
was performed according to Fritz et al., (2011). Briefly, the smooth muscle tissue was 
stabilised in a chamber for 1 h with a resting tension of 2-3 g, with changes of saline 
every 20 min. Tissue rings were then exposed to a solution containing 80 mM 
potassium or increasing concentrations of norepinephrine (10-6 and 10-7 M). For each 
condition, the contractile response was recorded. At the end of the experiment, tissue 
rings were dried on filter paper and weighed on a precision scale. The contraction 
intensity was calculated as the quotient between strength and the weight of the ring 
(mgF/mg).
2.5 Statistical analysis
The statistical analysis was performed with the GraphPad Prism 6.0 (GraphPad 
Prism Inc., CA, USA).The results obtained in in vivo experiments were expressed as 
means  standard error of the mean (SEM). In order to compare mean values, a one 
way analysis of variance (ANOVA) multiple comparisons was applied. The critical 
significance level was set at p < 0.05. The Least Significant Difference (LSD) test was 
used to analyse the results obtained in vivo.
3 Results 
3.1 Effect of the isolate, hydrolysate and emulsions containing amaranth 
peptides
The hypertensive rat is a suitable model to study systemic hypertension in 
humans caused by an increased production of angiotensin II produced by the action of 
ACE and renin. AH, O/W emulsions, VIKP and captopril presented inhibitory ACE 
activity in vitro, whereas AH and aliskiren inhibited renin in vitro (Table 1). The 
inhibitory activity of API was very low for both ACE and renin enzyme (Table 1). All 
samples, except Cw, caused a reduction of different magnitudes on the baseline 
systolic blood pressure (SBP), which was 19±3 mmHg on average. Figure 1 shows the 
reduction in the SBP values exerted in each experimental group. Values were 
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expressed as the decrease of SBP in mmHg of animals 3 h after the administration of 
each sample with respect to the SBP measured at the beginning of the experiment 
(SBP0hi-SBP3h). 
The decrease of SBP in the Gw group was 3 ± 8 mm Hg. The high dispersion 
observed in this parameter was due to an inter-individual variability presented by this 
experimental group. In animals treated with commercial anti-hypertensive drugs, the 
reduction in the SBP was 32  4 mmHg and 45  5 mmHg, for GC and GA groups, 
respectively. These animals reached blood pressure values somewhat higher than that 
corresponding to normotensive rats (~128mmHg) (Li et al., 2017, 2016); it is worth 
remembering that the treatment carried out with the samples under study was one 
dose treatment of 3 hours. The results obtained with GC and GA group are not 
surprising considering the localisation and action of renin and ACE in the RAS since 
renin is the rate-determining enzyme in the RAS system.
Animals belonging to the GE and GE+VIKP groups showed the most significant 
reduction in the SBP, reaching reduction values of 42 ± 2 mm Hg  and 35 ± 2 mm Hg, 
respectively. The administration of API, AH or VIKP in water as vehicle (GAPI, GAH y 
GVIKP groups) caused a reduction in SBP values that was significantly lower than those 
observed in the groups mentioned above (25 ± 14 mmHg, 26 ± 3 mmHg and 21 ± 3 
mmHg, respectively.) 
Our research group has recently demonstrated that an emulsion formulated with 
a mixture of amaranth protein isolate and hydrolysate (API + AH) can inhibit ACE in 
vitro (IC50 0.29 ± 0.03 mg/ml). Besides, an artificial digestion process does not 
abrogate the inhibitory capacity of the emulsion on ACE (IC50 0.13 ± 0.07 mg/ml 
(Suárez & Añón, 2019). These results strongly support the idea that either the anti-
hypertensive peptides present in the emulsion are resistant to proteolysis and/or that 
during the digestion process anti-hypertensive peptides are generated. These findings 
are in line with those of Tiengo et al., (2009), who demonstrated that protein 
hydrolysates from A. cruentus concentrates obtained with alcalase did not increase 
11
their inhibitory activity on ACE after gastrointestinal digestion, as compared with the 
undigested hydrolysate. The authors concluded that the peptides released by alcalase 
were resistant to the hydrolytic effect of digestive enzymes.
A few studies have demonstrated the reduction of the SBP in SHR rats by the 
administration of amaranth protein/peptides or other protein sources. Fritz et al., (2011) 
have demonstrated a 25 mmHg decrease in the SBP after 1.5 h post-administration of 
amaranth hydrolysates, with such effect lasting for 7 h. Working with hydrolysates of 
genetically modified amaranth 11S globulin (Medina-Godoy et al., 2013), and with 
amaranth protein hydrolysates obtained with alcalase (Ramírez-Torres et al., 2017), 
achieved reductions of blood pressure values of 20-25 mmHg and 28 mmHg, 
respectively, after 4 and 3 h post-administration, respectively. Hypotensive effects have 
also been achieved with other protein sources, such as bovine seroalbumin peptides 
(Lafarga, Rai, Connor, & Hayes, 2016), cod (Girgih et al., 2015), gelatin (Ngo et al., 
2015), and rice proteins (Li, Qu, Wan, & You, 2007).
To date, the present work and that of Fritz et al. (2011) and Ramírez-Torres et 
al. (2017) are the only ones evaluating the effect of amaranth hydrolysates prepared 
with alcalase on SHR rats.
3.2 Effects on plasma renin and ACE 
In order to assess the effect on the levels of RAS enzymes of each preparation 
administered orally, the concentration of ACE and renin were determined in each 
experimental group. Only the GA, GAPI and GAH groups presented differences in the 
plasma renin levels, as compared to the GW group (Figure 2 A). No differences were 
found in the levels of this enzyme between GC, GE, GVIKP and GE+VIKP groups and the 
control group GW.
A different behaviour was observed for the plasma levels of ACE. In Figure 2, 
B, it can be observed that the GW group presented extremely low values of ACE (0.17 
± 0.02 µg/ml), whereas the concentration of ACE in GC, GA, GE y GE+VIKP groups was 
13.6 to 25.8 times higher than that of the control group. The administration of the 
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isolate, the hydrolysate, and the peptide (GAPI, GAH, GVIKP groups, respectively) induced 
an increase in the ACE levels that was 7.6 to 5.3 times higher, as compared to the 
control group (1.3 ± 0.2 µg/ml, 0.90 ± 0.3 µg/ml and 1.1 ± 0.3 µg/ml, respectively, 
p<0.05). However, this increase was of a lower magnitude than that exerted by 
captopril, aliskiren and the emulsion with or without the peptide. 
Studies evaluating synthetic drugs for the treatment of hypertension have also 
demonstrated an increase in the levels of ACE in plasma and tissues. Chai, Perich, 
Jackson, Mendelsohn, & Johnston (1992) have found that lisinopril administered 
chronically (14 days, 10 mg/kg) to Sprague-Dawley rats induced a significant increase 
in ACE levels in plasma and lung tissue, but not in the aorta, testicles or kidneys. On 
the other hand, Masahairo et al., (1991) have found that the administration of the same 
drug chronically to the same strain of rats induced a 1.75-fold increase in the total 
plasma levels of ACE and of a 30% increase of the ACE levels in lungs, as compared 
to controls. These authors did not find any change in the levels of this enzyme in 
neither the kidneys, nor the adrenal glands, nor the aorta. In that work, it was also 
found that during the treatment, the ACE activity in these organs could be inhibited with 
low levels of free ACE. 
The increase of ACE in plasma and lungs does not seem to decrease the 
efficacy of ACE inhibitors in patients with chronic hypertension or chronic heart failure 
(Chai et al., 1992).
The activity of ACE in plasma was then determined in order to assess whether 
the increased levels of this enzyme after the administration of conventional ACE and 
renin inhibitors and the API + AH emulsion formulated with or without VIKP has any 
biological relevance. As shown in Figure 3, the ACE activity was found to be inversely 
proportional to its plasma concentration. The lowest activity values (4-7 % active 
ACE/µg plasma ACE) corresponded to groups GC, GA, GE and GE+VIKP, whereas the 
highest activity values were found in the GVIKP, GAH and GAPI groups, which presented 
20-13% active ACE/µg plasma ACE.
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Taken together, these results would indicate that the action of ACE competitive 
inhibitors, such as captopril or the hypotensive amaranth peptides either present in the 
samples or generated during the gastrointestinal digestion, induce the synthesis of 
considerable amounts of plasmatic ACE with low activity. 
3.3 Effect of amaranth anti-hypertensive peptides on the vascular system 
To determine whether the vasorelaxant effect observed after the ingestion of 
amaranth proteins/peptides is only due to their competitive inhibitory effect on the RAS 
enzymes, the contractile activity of thoracic aorta rings was determined in the presence 
of potassium ions and norepinephrine. These compounds are known to cause 
vasoconstriction through the action upon voltage- and receptor-operated channels, 
respectively (Rinaldi, 1990)
The contractile activity determined in the presence of potassium ions was 
higher in the GW, GC and GA groups (roughly 0.45 g/mg), whereas this activity was 
significantly lower in the animals belonging to groups GAPI, GVIKP, GE+VIKP, GAH and GE 
(0.34 to 0.29 mg/g, Figure 4,A). Upon treating aorta rings with physiological 
concentrations of norepinephrine (Figure 4,B), statistically differences were observed 
in the, GVIKP and GE+VIKP groups.
Potassium ions cause depolarisation of the plasma membrane and allow the 
opening of type L calcium channels through which calcium ions enter and cause 
contraction of the myofibrillar system (Rinaldi, 1990). Norepinephrine binds to -
adrenergic receptors and, to a lesser extent, to β-adrenergic receptors to allow a rapid 
release of intracellular calcium and a subsequent influx of extracellular calcium, 
causing vascular contraction (Grand & Rinaldi, 1990; Rinaldi, Grand, & Cingolani, 
1991).
The fact that no reduction in the contractile activity was found in the aorta rings 
treated with potassium and norepinephrine in the GC and GA groups was expected, 
since it is known that both compounds are competitive inhibitors of plasma ACE and 
renin, respectively (Bernstein et al., 2013). For groups GAPI, GAH, GVIKP, GE and GE+VIKP, 
14
a selective action of amaranth proteins/peptideson the membrane polarity was 
observed. An interaction with adrenergic receptors was only observed in the groups 
treated with the peptide (GVIKP and GE+VIKP). These findings suggest that the amaranth 
peptides can exert a double effect, i.e., an overall effect on the membrane 
depolarisation and the opening of type L channels, and a specific effect exerted by 
VIKP peptides on - and β-adrenergic receptors. In a previous work (Fritz et al., 2011) 
we demonstrated that norepinephrine caused a strong contraction of aorta rings. After 
rinsing, and 30 min after incubation with an amaranth hydrolysate, a marked 
vasorelaxant effect was observed in strength vs. norepinephrine concentration curves. 
The vasorelaxant effect exerted by the hydrolysate remained even in the presence of 
L-NAME, indicating that the effect was not endothelium-dependent, contrary to the 
observations made by Barba de la Rosa et al. (2010) when working with amaranth 
glutenins. In the present work, aorta rings from rats treated with the different 
preparations were stimulated only with potassium and norepinephrine, i.e., in the 
absence of amaranth proteins. Even under these experimental conditions, a 
vasorelaxant effect was observed in animals treated with the synthetic peptide, which 
indicates that these peptides have a residual vasorelaxant effect. According to Fujita & 
Yoshikawa, (1999), peptides derived from food have higher affinity for the tissues and 
are cleared from the body more slowly than other inhibitors, such as captopril. These 
findings agree with our results. Fritz et al., (2011) did not observe an inotropic effect 
when they carried out ex vivo assays with isolated papillary muscles, which indicates 
that, in vivo, the hypotensive effect is not driven by diminishingthe heart activity, but by 
a decrease in the vascular peripheral resistance.
4 Conclusions
This work provide an advance in the knowledge of the properties of amaranth 
proteins, demonstrating that API, AH, synthetic peptides (VIKP) and API50:AH50 with 
or without VIKP emulsions, administered in a single dose for only 3 hours, can reduce 
the SBP in SHR rats from values of 200-220 mmHg to values of 140-170 mmHg. The 
15
most active preparations were the emulsions formulated with API50:AH50 with or 
without VIKP that induced a reduction in SBP greater than that produced by equivalent 
or lower amounts, and equal measurement time after administration of amaranth 
hydrolysates or other proteins sources such as cod and rice. On the other hand, the 
SBP reduction values achieved by VIKP were similar to those obtained by 
administering the same dose of peptides of a genetically modified amaranth 11S 
globulin hydrolysate. Experiments in this work confirm the initial hypothesis, the 
decrease in SBP values can be attributed at least to two mechanisms of action of the 
amaranth peptides (Figure 5): their activity as competitive inhibitors of the main plasma 
enzymes of the RAS, i.e., ACE and renin, and, their effect as vasorelaxant agents on 
the vascular system. The administration of API, AH, synthetic peptides (VIKP) and 
API50:AH50 with or without VIKP emulsions decrease the enzymatic activity of ACE, 
together with an increase in plasma levels, probably to counter balance the inhibitory 
effect exerted by the peptides. On the other hand, the plasma levels of renin are only 
increased after the administration of aliskiren, API and AH, being the effect weaker 
than that observed for ACE. AH, VIKP and API50:AH50 emulsions with or without 
VIKP, have also an autocrine effect on RAS, inducing a vasorelaxation that persists 
even in the absence of the effector molecule. This vascular effect is achieved through a 
membrane depolarisation phenomenon and through direct interaction of VIKP with 
adrenergic receptors. This effect is endothelial NO-independent (Fritz et al., 2011). The 
results presented herein strongly suggest that after the gastrointestinal digestion, a 
variety of peptides with biological activity are released. These peptides play a role in 
the regulation of the blood pressure by acting on plasma ACE, plasma renin and the 
vascular system. Another alternative or concomitant phenomenon may be the 
resistance to in vivo hydrolysis of peptides present in the AH and in emulsions, as well 
as VIKP.
These results support the use of amaranth protein/peptides in the elaboration of 
complementary functional foods for hypertensive individuals.
16
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5 Figure Captions.
Figure 1. Changes in systolic blood pressure of SHR after 3 hour treatment with: Cw: 
water, CA: aliskiren, CC: captopril, API: amaranth isolated,. AH: amaranth hydrolysate, 
VIKP: synthetic peptide from amaranth protein, E: O/W 20:80 emulsions, E + VIKP: 
O/W 20:80 emulsions + synthetic peptide. ΔP values are presented as mean ± SEM. 
(*) mean significantly different compared to Cw (p < 0.05).
Figure 2.(A) Plasma renin concentration and (B) plasma ACE concentration at the end 
of the 3 hours treatment. Cw: water, CA: aliskiren, CC: captopril, API: amaranth 
isolated,. AH: amaranth hydrolysate, VIKP: synthetic peptide from amaranth protein, E: 
O/W 20:80 emulsions, E + VIKP: O/W 20:80 emulsions + synthetic peptide. Data are 
presented as mean ± SEM. (*) mean significantly different compared to Cw (p < 0.05).
Figure 3. Plasma ACE activity. CA: aliskiren, CC: captopril, API: amaranth isolated,. 
AH: amaranth hydrolysate, VIKP: synthetic peptide from amaranth protein, E: O/W 
20:80 emulsions, E + VIKP: O/W 20:80 emulsions + synthetic peptide. This data are 
expressed as relative to 100% ACE activity to water control group (Cw). Data are 
presented as mean ± SEM. (*) mean significantly different compared to Cw (p < 0.05).
Figure 4. Effect of different samples on isolated aortic rings contracted by exposure to 
a high concentration of: (A) Potassium ion (80 mM). (B) Norepinephrine (10-6 M). CA: 
aliskiren, CC: captopril, API: amaranth isolated,. AH: amaranth hydrolysate, VIKP: 
synthetic peptide from amaranth protein, E: O/W 20:80 emulsions, E + VIKP: O/W 
20:80 emulsions + synthetic peptide. Data are presented as mean ± SEM. (*) means 
significantly different compared to Cw (p < 0.05).
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Table 1. IC50 values for in vitro inhibition of renin and ACE of the samples tested
Sample ACE IC50 renin IC50
Captopril 39.2±11.2 nM N. D.
aliskiren N. D. 0.6 nM (**)
API 0.7 ± 0.2 mg/mL(*) > 13 mg/mL
AH 0.14±0.02 mg/ml 0.6 mg/mL
VIKP 0.175 uM non active
(O/W) Emulsion 0.29±0.03 mg/ml non active 
N.D. not determined.
(*) Aphalo, Martínez & Añón International Journal of Food Properties, 18:2688–2698, 2015
(**) Yongfei Chen, Long Meng, Hua Shao & Feng Yu. Hypertension Research (2013) 36, 252–261
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Highlights
 Amaranth peptides produce a very significant decrease in blood pressure in 
SHR rats
 These peptides have an effect on ACE and renin plasma level and ACE activity 
 Amaranth peptides produce depolarization of membranes which causes 
vasorelaxation
 Synthetic peptide VIKP also acts on b-adrenergic receptors causing 
vasorelaxation
 Amaranth peptides act at both levels, on blood vessels and on RAS enzymes 
